Interferon as an adjuvant treatment for melanoma; registered but not indicated;Interferon als adjuvante therapie bij het melanoom: Wel geregistreerd, niet geindiceerd

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 45, 2000, Pages 2160-2162

  Groenewegen, G ^a   Osanto, S ^a   Van Der Rhee, H J ^a   Punt, C J A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDICATION; HUMAN; MELANOMA; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG APPROVAL; HUMANS; INTERFERON ALFA-2A; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; NETHERLANDS; PRACTICE GUIDELINES;

EID: 0034605782     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Tweede herziene consensus melanoom van de huid
2. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
3. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
4. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
5. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
6. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
7. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111.C9190